News Gator Bio Launches HIS XT Probes with AI-Designed NovoBody™ Technology, Delivering Superior Performance for His-Tagged Protein Analysis Industry-first probes featuring computationally designed binding proteins provide unprecedented affinity, baseline stability, and data quality for antibody characterization and biologics research PALO ALTO, CA & Seattle, WA, February 18, 2026 — Gator Bio, a pioneer in biolayer interferometry (BLI) technologies, today announced the commercial launch of its Gator HIS XT probes, the first biolayer interferometry probes to incorporate AI-designed binding proteins. Developed in partnership with Monod Bio, the HIS XT probes feature Monod’s proprietary NovoBody™ anti-His binding protein, delivering superior affinity for His-tagged proteins with industry-leading baseline stability and signal resolution. The HIS XT probes achieve high-capacity capture of His-tagged proteins with exceptionally stable baselines, enabling precise kinetic analysis and reliable quantitation. The AI-designed NovoBody coating provides 4x higher signal resolution compared to traditional anti-His probes, allowing researchers to detect weak interactions and analyze small analytes with confidence. Additionally, the probes eliminate Fc-mediated interference that can generate false-positive signals in traditional mouse monoclonal antibody-based sensors, making them ideal for studying Fc-interacting partners such as Fc receptors and complement proteins. The HIS XT probes deliver superior baseline stability with 58% reduction in signal drift, enabling confident measurement of picomolar affinities and accurate quantitation of His-tagged proteins. The probes support both one-step and two-step quantitation workflows and are compatible with high-throughput epitope binning experiments, with complete characterization of 256 antibody pairs achievable in under 4 hours. “Our customers are at the forefront of biologics development, and they need tools that deliver superior performance and reliability,” said Hong Tan, PhD, CEO of Gator Bio. “The HIS XT probes set a new standard for His-tag analysis with exceptional affinity, baseline stability, and data quality required for cutting-edge antibody engineering and multispecific protein characterization.” “The launch of the HIS XT probes represents a significant milestone in bringing AI-designed proteins from concept to commercial reality,” said Daniel Silva Manzano, PhD, CEO of Monod Bio. “This product validates our vision that computationally designed binding proteins can outperform traditional antibodies in demanding research applications.” Customer Validation Confirms Superior PerformanceBeta testing with leading biologics companies demonstrated the HIS XT probes’ exceptional performance across diverse applications. “We are pretty impressed,” said Zachary A. Bornholdt, PhD, CEO of Eitr Biologics, Inc. “These HIS XT probes effectively eliminate Fc-mediated interactions and can be reliably used to assess direct binding or in other experiments with Fc-interacting partners with confidence. We are very interested in incorporating this product into our workflow.” Additional beta testing confirmed the probes’ versatility and data quality. “We evaluated Gator’s new HIS XT probes in an epitope binning study and observed excellent performance,” said Allison Nixon, Head of Platform Sciences at Ability Biotherapeutics. “The probes showed ideal capture behavior, high-quality kinetic traces, and robust regeneration. The resulting data was clean and straightforward to interpret, enabling rapid, actionable insights.” David Ichikawa, Scientist III, Neochromosome, Inc. said “The HIS XT probes gave less error, and results were closer to the published dissociation constant. They also load ~2x as much of the same protein prep in half the time as traditional anti-His probes. Overall, the signal is much cleaner/more stable. Also, it’s cool to watch these capture his-tagged nanobodies out of supernatant from our neoSwitch strain!” AvailabilityThe Gator HIS XT probes are available for order immediately. For more information or to place an order, visit www.gatorbio.com or contact [email protected]. ### About Gator BioGator Bio is a leading innovator in label-free biosensor technology, delivering high-performance analytical instruments for biomolecular interaction analysis. The company’s biolayer interferometry (BLI) platform serves as a critical validation technology for AI-driven protein design, providing researchers with powerful tools for real-time, quantitative characterization of next-generation biologics including computationally designed proteins and antibodies. For more information, visit gatorbio.com. About Monod BioMonod Bio is a Seattle-based biotechnology company and a spinout from the David Baker Lab at the University of Washington’s Institute for Protein Design. The company uses AI-powered de novo protein design to create novel protein binders and biosensors for research use only (RUO) and in vitro diagnostic (IVD) applications. Monod Bio’s proprietary platform enables the generation of novel proteins, including its NovoBody™ binders, to address unmet needs. Through its “Monod Inside” business model, Monod Bio partners with leading RUO and IVD organizations to bring next-generation products to market. For more information, visit monod.bio. Media ContactNiño FloroSenior Marketing ManagerEmail: [email protected]Phone: 855.208.0743
News Gator Bio and Hudson Lab Automation Announce Proven High-Throughput BLI Automation Solution Integrated Platform Enables up to 3X Higher Throughput for Antibody Discovery and Characterization; Joint Solution Addresses Growing Demand from AI Drug Design Companies, Pharma, and CROs PALO ALTO, CA and SPRINGFIELD, NJ – February 9, 2026 — Gator Bio, a leader in biolayer interferometry (BLI) systems, and Hudson Lab Automation, Inc., a leading laboratory automation provider, today announced the availability of their proven integrated automation solution for high-throughput antibody discovery and characterization. The companies will showcase the solution at the SLAS 2026 International Conference and Exhibition, February 7-11 in Boston, MA. The Gator Bio Pivot and Pro BLI systems, integrated with Hudsons’ PlateCrane automation platform, deliver a production-ready solution that can increase sample throughput from 400 to 1,200+ samples per day, a 3X capacity increase depending on workflow configuration. This addresses a critical bottleneck for organizations scaling antibody discovery programs, particularly those leveraging AI-designed antibody libraries that generate thousands of candidates requiring rapid characterization. “The combination of modern BLI technology with proven robotic automation is exactly what the market has been asking for,” said Hong Tan, CEO of Gator Bio. “AI drug design companies, large pharma, and CROs are all capacity-constrained when it comes to antibody screening and characterization. Our collaboration with Hudson delivers an integrated solution that’s proven in production environments and deployment ready today.” The integrated platform was demonstrated at the Antibody Engineering & Therapeutics conference in December 2025, where it generated significant interest from pharma and biotech organizations seeking to scale their discovery operations without proportionally scaling headcount. Key benefits of the Gator + Hudson solution include: 3X Throughput Increase: Process 1,200+ samples per day vs. 400 manually, enabling 24/7 continuous operation Proven Integration: Production-ready system with validated protocols, not proof-of-concept Broad Application Coverage: Gator’s 30+ off-the-shelf biosensor portfolio supports diverse applications from hybridoma screening to complex kinetics and emerging modalities like bispecific and AAV characterization Flexible Scalability: Start with basic automation (60-plate capacity) and expand to 450+ plates as needs grow Open Platform Approach: Gator’s automation-friendly design works with any robotic vendor, giving customers choice and flexibility “Hudson Lab Automation is excited to partner with Gator Bio to deliver high-throughput solutions for the rapidly growing antibody discovery market,” said Werner Maas, CEO of Hudson Lab Automation. “Successful automation depends on orchestration, not just robotics.” Hong Tan, Founder and CEO of Gator Bio added: “Through our collaboration with Hudson, we’ve integrated their plate automation and SoftLinx scheduling software into a scalable BLI workflow that supports continuous operation today and expansion as customer needs evolve. This addresses an unmet need in the pharma and biotech community and validates the strong market demand for this integrated approach.” The solution is particularly well-suited for organizations working with AI-designed antibody libraries, which can generate thousands of candidates requiring characterization. Traditional manual BLI workflows cannot keep pace with AI-generated discovery throughput, creating a critical bottleneck. The Gator + Hudson automation platform eliminates this constraint, enabling researchers to fully leverage AI-driven discovery while maintaining rigorous characterization standards. Target applications include: High throughput hybridoma and yeast display screening Affinity ranking and epitope binning for large antibody panels Full kinetic characterization for lead optimization Bispecific and multi-specific antibody development AAV capsid characterization and selection Manufacturing process development and QC workflows To accelerate customer adoption and simplify procurement, Gator Bio is introducing a comprehensive Gator Pro + Hudson Automation Bundle Package. Customers receive significant cost savings compared to purchasing systems separately, while also receiving a comprehensive 2-year warranty on both systems. This turnkey package enables organizations to rapidly deploy production-ready automation without the complexity of multi-vendor negotiations. Visit Gator Bio and Hudson Lab Automation at SLAS 2026: Gator Bio Booth: 2545 Hudson Lab Automation Booth: 416 Joint demonstrations available at Booth 2545 For more information about the Gator Bio + Hudson Lab Automation solution, visit https://www.gatorbio.com/high-throughput-automation/ or contact [email protected]. ### About Gator Bio Gator Bio is a bioanalytical instrumentation company specializing in biolayer interferometry (BLI) systems for antibody discovery, characterization, and process development. The company’s Pivot and Pro instruments offer researchers modern BLI technology with the industry’s broadest off-the-shelf biosensor portfolio of over 30 sensors covering applications from early discovery through manufacturing. Gator Bio’s automation-friendly platform design enables seamless integration with leading laboratory automation vendors, providing customers with flexible, scalable solutions for high-throughput operation. Founded by Hong Tan, inventor of the original Octet BLI platform, Gator Bio is headquartered in Palo Alto, California. For more information, visit www.gatorbio.com. About Hudson Lab Automation Hudson Lab Automation is a leading provider of flexible laboratory automation solutions for life science research and drug discovery, known for intuitive and reliable instrumentation. Hudson designs and produces stand-alone productivity and reproducibility enhancing instruments and scalable robotic systems, liquid handling platforms, and workflow orchestration software that enable modern laboratories to achieve real-world throughput with confidence. With decades of experience deploying automation in pharma, biotech, CRO, and academic environments, Hudson’s proven platforms are deployed globally, enhancing numerous life science workflows. For more information, visit www.hudsonlabautomation.com Media Contacts: Gator BioSriram KumaraswamyVP of Marketing and Product ManagementEmail: [email protected]Phone: 855.208.0743 Hudson Lab AutomationSara MackeyVP Sales & MarketingEmail: [email protected]Phone: 973.376.7400
News Monod Bio and Gator Bio Partner to Develop Next-Generation Biosensors for Advanced Life Science Research Gator will integrate one of Monod’s AI-designed NovoBody™ binding proteins into its industry-leading biolayer interferometry platform NovoBody™ binding proteins deliver superior performance, stability, and engineerability compared to traditional monoclonal antibodies Seattle, WA & Palo Alto, CA — December 3, 2025 — Monod Bio, a leader in computational protein design, and Gator Bio, a pioneer in biolayer interferometry (BLI) technologies, today announced a partnership to integrate one of Monod’s proprietary AI-designed NovoBody™ protein binders into Gator’s biosensor platform. The collaboration combines Monod’s advanced AI-based protein design technology with Gator’s proven BLI platform to deliver next-generation biosensing capabilities. Under the terms of the license agreement, Monod will supply NovoBody™ binding proteins to Gator Bio for use in a new biosensor product offering, one of the first to incorporate an AI-designed binding molecule. Gator Bio will oversee manufacturing, sales, and marketing of the biosensor, while Monod will receive upfront, supply, and royalty payments. The product launch is anticipated in the first half of 2026. “Our collaboration with Gator Bio marks a significant milestone in the adoption of computationally designed binding proteins for biosensing applications, paving the way for broader use of NovoBody™ binding proteins across life science research and diagnostics,” said Daniel Silva Manzano, PhD, CEO of Monod Bio. “NovoBody™ binding proteins are computationally designed to deliver superior stability, manufacturability, and performance compared to traditional antibodies.” “At Gator Bio, we are positioned at the intersection of AI innovation and experimental validation,” said Hong Tan, PhD, CEO of Gator Bio. “Our BLI instruments are a critical enabling technology for the AI protein design revolution, providing the real-time, label-free characterization that validates computationally designed molecules. By incorporating AI-designed NovoBody™ binding proteins into our biosensor portfolio, we are both advancing and benefiting from the AI transformation of biologics development.” “This collaboration exemplifies our ‘Monod Inside’ business model,” said Carl Walkey, PhD, VP of Business Development at Monod Bio. “By integrating NovoBody™ binding proteins into leading industry platforms like Gator’s, we’re enabling partners to rapidly bring breakthrough products to market.” About Monod BioMonod Bio is a Seattle-based biotechnology company and a spinout from the David Baker Lab at the University of Washington’s Institute for Protein Design, co-founded by Daniel Silva Manzano, Alfredo Quijano-Rubio, and David Baker. The company is a leader in de novo protein design to create novel protein binders and biosensors for research use only (RUO) and in vitro diagnostic (IVD) applications. Monod Bio’s proprietary AI platform enables the generation of novel proteins using in silico methods, including its NovoBody™ binders, to address unmet needs. Through its “Monod Inside” business model, Monod Bio partners with leading RUO and IVD organizations to bring next-generation products to market. For more information, visit http://monod.bio. About Gator Bio Gator Bio is a leading innovator in label-free biosensor technology, delivering high-performance analytical instruments for biomolecular interaction analysis. The company’s biolayer interferometry (BLI) platform serves as a critical validation technology for AI-driven protein design, providing researchers with powerful tools for real-time, quantitative characterization of next-generation biologics including computationally designed proteins and antibodies. For more information, visit gatorbio.com
News Gator Bio Launches Gator® Pilot and Gator® Pivot Biolayer Interferometry Systems for Biotherapeutics Discovery Read at PR Newswire
News Administrative Law Judge Issues Initial Determination In Bio-Layer Interferometers Investigation Read at PR Newswire
News Gator Bio Signs Exclusive Distribution Agreement with GeneX India Bioscience Gator Bio in partnership with GeneX India Bioscience is ready to serve the biotherapeutics research and manufacturing with next-gen biolayer interferometry PALO ALTO, CA, UNITED STATES, April 18, 2023/EINPresswire.com/ — Gator Bio, the next-gen biolayer interferometry solutions company, has signed an agreement with GeneX India Bioscience Pvt Ltd, a Chennai-based distributor of innovative biomedical technology and products. The agreement will allow Gator Bio to expand its product offerings rapidly in India, a key region for Gator Bio’s global growth strategy. Dr. Hong Tan, CEO of Gator Bio, said, “GeneX India has a track record of successfully introducing innovative products into market — as evidenced by its previous success in commercializing e.g., PEIpro, Double Dye Probe, FectoPRO etc. We look forward to working with the GeneX India team to bring the Gator platforms to users throughout the region, helping meet the demand for therapeutics development and manufacturing.” “Gator BLI platforms and innovative biosensors are an important addition to GeneX India’s portfolio of Cell and Gene Therapy, Protein Biology products, and we are very excited about the possibilities the Gator shall give our customers in characterizing antibodies, AAVs and small molecule drugs,” said Mr. Felix Paul, CEO of GeneX India. “Access to this next-gen technology is key to the continued enablement of our biopharma and academia research customers in India. We are very excited about helping research and manufacturing community with the novel applications in gene therapy, immunotherapy, and lipid nanoparticle development.” This partnership builds on Gator Bio’s commitment to providing high-quality BLI platforms globally. Gator Bio has recently entered into strategic partnerships with BMS Korea (Bio Medical Sciences), I&L Biosystems in Europe and Solve Scientific in Australia to provide sales and services to biotherapeutics and gene therapy companies. To learn more, please visit www.gatorbio.com. About Gator Bio, Inc.Gator Bio is a life sciences company providing bioanalytical systems to accelerate the development of therapeutics and diagnostics. The Gator next-gen biolayer interferometry (BLI) instruments and biosensors enable real-time analysis of biomolecular interactions providing information on affinity, kinetics, concentration and epitope binning, etc. Most importantly, Gator Bio’s analytical capabilities enable better and faster characterization of drug candidates and viral vectors, thus providing greater value in drug development and gene therapy applications where existing methods have limitations in throughput, performance, and cost. The company is headquartered in Palo Alto, California with facilities in Shanghai and Suzhou, China. For more information, please visit www.gatorbio.com Subodh NimkarGator Bio+1 650-575-0827email us hereVisit us on social media:LinkedIn
News Gator® Pro Press Release Gator Bio launches Gator® Pro, a high throughput and high performance next-gen BLI system, for biotherapeutics discovery NEWS PROVIDED BY Gator Bio January 13, 2023, 20:46 GMT Gator Bio aims to set a new industry standard for high throughput and accurate kinetics, epitope binning and quantitation for biotherapeutics discovery PALO ALTO, CA, UNITED STATES, January 13, 2023 /EINPresswire.com/ — Today, Gator Bio, Inc. announced the launch of Gator® Pro, a high throughput and high performance BLI system for biotherapeutics development. The system is capable of 32-channel high frequency data acquisition in parallel. Combined with the new Gator® Screener software, the total solution delivers high-quality kinetics and epitope binning results in fraction of the time taken by traditional BLI and SPR systems. The new high throughput Gator® Pro expands the current next-gen BLI instrument portfolio that includes the 8-channel Gator® Prime and Gator® Plus systems. “Antibody and protein therapeutics developers repeatedly ask for more efficient BLI solutions that combine throughput and performance. We believe Gator® Pro addresses those needs. It can also complement SPR as a high throughput screening tool.” said Dr. Hong Tan, CEO of Gator Bio. “We are singularly focused on delivering easy, efficient and effective solutions that would enable scientists to develop biotherapeutics faster”. Detailed info for the Gator® Pro along with Gator Bio’s complete portfolio of next-gen BLI products can be found here. About Gator Bio, Inc.Gator Bio is a life sciences company providing analytical solutions to accelerate the development of therapeutics and diagnostics. The Gator instruments and biosensors enable real-time analysis of biomolecular interactions providing information on affinity, kinetics, concentration, and epitope binning, etc. Most importantly, Gator Bio’s analytical capabilities enable better and faster characterization of drug candidates and viral vector analytics, thus providing greater value in drug development and gene therapy applications, where existing methods have limitations in throughput, performance, and cost. The company is headquartered in Palo Alto, California. For more information, please visit www.gatorbio.com. SOURCE Gator Bio, Inc.Media and Investor Relations Contact:Subodh Nimkar, Marketing Director[email protected]+1 650 575 0827 Subodh NimkarGator Bio+1 650-575-0827email us hereVisit us on social media:LinkedInYouTube
News Gator Bio Strengthens the Portfolio of AAV Analytics for Gene Therapy with Solutions for Each Step of Bioprocessing The AAV Titer and Empty/Full Ratio Determination in Upstream Crude Samples is Challenging. The New Gator Assays Offer a Practical Cost-Effective Solution SAN JOSE, CA, UNITED STATES, November 15, 2022 /EINPresswire.com/ — Today, Gator Bio, Inc. announced the launch of Gator® AAV Ratio Kit, High Sensitivity AAV Kit and High Sensitivity AAV9 Kit for empty vs full ratio determination and titer, respectively. The assays run on FDA 21 CFR Part 11 compliant Gator® Prime and Gator® Plus biolayer interferometry (BLI) instruments. This is the only automated single platform solution in the market capable of accurate and easy determination of titer and empty vs full ratios at every stage of the AAV development and production. The automated Gator® High Sensitivity AAV Kit and High Sensitivity AAV9 Kit enable titer determination with the widest dynamic range for serotypes 1-10 in crude and purified samples. This kit fits into every stage of the AAV processing workflow, and the titer measurements correlate well with the gold standard methods. The Gator® AAV Ratio Kit is an innovative empty vs full method that easily and accurately measures ratios from 5-100% full capsids in crude and purified samples. Along with its simplicity, good AUC correlation, short time-to-result, and cost effectiveness, the Gator® AAV Ratio Kit will fundamentally change how this analysis is routinely done. Enabling gene therapy developers and manufacturers with cutting-edge tools is Gator Bio’s focus. “There are many challenges and new demands in AAV and other vector analytics, and we are dedicated to developing practical solutions leveraging Gator’s next-gen BLI and novel chemistry know-how” said Dr. Hong Tan, CEO of Gator Bio. “We are singularly focused on delivering easy, efficient and cost-effective solutions”. Detailed info for the newly released solutions along with Gator Bio’s complete portfolio of products can be found at –https://www.gatorbio.com/applications/gene-therapy/ About Gator Bio, Inc.Gator Bio is a life sciences company providing analytical solutions to accelerate the development of therapeutics and diagnostics. The Gator instruments and biosensors enable real-time analysis of biomolecular interactions providing information on affinity, kinetics, concentration, and epitope binning, etc. Most importantly, Gator Bio’s analytical capabilities enable better and faster characterization of drug candidates and viral vector analytics, thus providing greater value in drug development and gene therapy applications, where existing methods have limitations in throughput, performance, and cost. The company is headquartered in Palo Alto, California. For more information, please visit www.gatorbio.com. SOURCE Gator Bio, Inc.Media and Investor Relations Contact:Subodh Nimkar, Marketing Director[email protected]+1 650 575 0827 Subodh NimkarGator Bioemail us here+1 6505750827Visit us on social media:LinkedIn
News Gator Bio is ISO 9001 Certified! Gator Bio is proud to announce achievement of ISO 9001:2015 certification for our manufacturing facility, a globally recognized certification of quality management system standards. This further communicates Gator Bio’s commitment to develop processes ensuring consistency, reliability, and accountability across our business operations. By achieving this level of certification, Gator Bio continues to demonstrate our competence and desire to effectively and efficiently provide a quality management system while continuously improving our products, services, and internal processes. We strive to consistently meet and exceed expectations of our customers.